혈액 정화 장비 시장 : 모달리티별, 용도 및 임상 적응별, 최종 사용자별, 지역별 - 시장 규모, 업계 역학, 기회 분석 및 예측(2026-2035년)

The blood purification equipment market was valued at approximately USD 20.68 billion in 2025 and is projected to reach around USD 40.11 billion by 2035, expanding at a compound annual growth rate (CAGR) of 6.85% over the forecast period from 2026 to 2035. This steady growth trajectory reflects the increasing global reliance on advanced extracorporeal therapies for managing both chronic and acute renal conditions, alongside broader improvements in healthcare access and critical care infrastructure.

A key underlying driver of this expansion is the rising prevalence of Chronic Kidney Disease, which continues to escalate due to the global burden of diabetes, hypertension, obesity, and aging-related physiological decline. As CKD progresses to end-stage disease, patients require long-term renal replacement therapies such as dialysis, creating sustained and recurring demand for blood purification systems across hospitals and specialized dialysis centers.

Noteworthy Market Developments

The competitive landscape of the blood purification equipment market is characterized by a high degree of consolidation at the top, alongside increasing pressure from venture-backed innovators seeking to disrupt established industry structures. Leading multinational players such as Fresenius Medical Care, Baxter International, B. Braun, and Nikkiso maintain dominant positions through extensive economies of scale, vertically integrated business models, and long-standing contractual relationships with hospitals and dialysis networks.

These established players are increasingly focusing their strategic efforts on protecting existing market share while simultaneously transitioning toward value-based care ecosystems. This includes integrating digital health platforms, remote monitoring capabilities, and data-driven clinical management tools into their product offerings, allowing them to align more closely with evolving reimbursement models and outcome-based healthcare frameworks.

At the same time, specialized manufacturers such as Asahi Kasei Medical and Toray Industries continue to hold strong positions in niche but critical segments, particularly high-flux dialyzers and advanced apheresis cartridges. Their expertise in membrane technology and filtration science allows them to maintain leadership in high-performance consumables that are essential to modern blood purification therapies.

Core Growth Drivers

The aging of the global population is a major structural driver accelerating demand in the blood purification equipment market. The steady "graying" of societies, particularly in regions such as Japan, Western Europe, and North America, is closely associated with a higher prevalence of chronic comorbidities that contribute to kidney dysfunction, including diabetes, hypertension, and cardiovascular disease. As a result, older populations exhibit a significantly increased risk of developing End-stage Renal Disease, thereby expanding the long-term patient pool requiring renal replacement therapies such as dialysis.

Emerging Opportunity Trends

The integration of Artificial Intelligence and machine learning has emerged as the primary technological disruptor in the blood purification equipment market. In modern hemodialysis systems, advanced algorithms are increasingly embedded into device software to process continuous physiological data in real time, particularly from blood volume monitoring sensors. These intelligent systems are capable of identifying subtle hemodynamic trends during treatment sessions and dynamically adjusting ultrafiltration rates to maintain hemodynamic stability.

Barriers to Optimization

Despite robust demand, the operational landscape for manufacturers in the blood purification equipment market is increasingly constrained by significant supply chain disruptions and material sourcing challenges. This friction is especially pronounced in the production of advanced systems such as Continuous Renal Replacement Therapy (CRRT) devices and home hemodialysis machines, which depend on highly sophisticated electronic components for precise fluid control, pressure regulation, and pump calibration. These systems require specialized microchips to ensure real-time monitoring and accuracy, making them particularly vulnerable to global semiconductor supply fluctuations.

Detailed Market Segmentation

By type, the dialysis segment continues to hold the largest market share in the blood purification equipment market, reflecting its indispensable role in managing advanced kidney failure across global healthcare systems. This dominance is primarily driven by the substantial epidemiological burden of End-stage Renal Disease, which necessitates sustained and structured treatment rather than episodic intervention. As a result, dialysis remains the cornerstone therapy for patients who have progressed beyond conservative management options, ensuring consistently high demand for both equipment and associated consumables.

By product, the portable segment accounted for more than 82% of revenue share in the blood purification equipment market, reflecting a clear structural shift in how dialysis and related therapies are being delivered globally. Rather than being an anomaly, this dominance is closely linked to the accelerating adoption of Home Hemodialysis (HHD) and the expanding use of point-of-care solutions for acute and critical care settings. Portable blood purification systems have become increasingly central to modern renal care strategies because they enable treatment delivery outside traditional hospital dialysis units, offering greater flexibility and scalability in both developed and emerging healthcare systems.

By modality, the hemodialysis (HD) segment is projected to have held a dominant position in the blood purification equipment market in 2025. This leadership is largely attributed to its long-established role as the default standard of care for patients with advanced kidney dysfunction, particularly those suffering from Chronic Kidney Disease. Hemodialysis has been integrated into healthcare systems for decades, resulting in well-developed clinical infrastructure, trained personnel, and standardized treatment protocols across hospitals and dedicated dialysis centers. As a result, it remains the most widely accessible and operationally scalable modality for managing end-stage renal disease patients compared to alternative approaches.

By application, the renal disease application segment is anticipated to generate the highest revenue over the forecast period. This dominance is primarily driven by the persistent and irreversible nature of conditions such as Chronic Kidney Disease and end-stage renal failure, which require ongoing and often lifelong therapeutic interventions. Unlike acute conditions that may be treated and resolved, renal failure creates a continuous demand cycle for dialysis and related blood purification procedures, ensuring steady utilization of equipment across hospitals, specialized nephrology centers, and standalone dialysis clinics.

Segment Breakdown

By Modality

• Hemodialysis (HD)
• Dialyzers (Hemodialysis filters)
• Bloodlines and Tubing Sets
• AV Fistula Needles
• Dialysate Connectors and Cartridges
• Drip Chambers
• Heparin Lines / Syringe Sets
• Inline Filters / Air Traps
• Continuous Renal Replacement Therapy (CRRT)
• Hemofilters (CRRT filters)
• CRRT Tubing Sets / Circuits
• Replacement Fluid / Dialysate Bags
• Access Catheters (Double/Triple Lumen)
• Flush Kits / Priming Sets
• Pressure Monitoring Line Sets
• Anticoagulation Cartridges / Lines
• Hemoperfusion
• Hemoperfusion Cartridges (Resin/Charcoal)
• Adsorber Column Connectors
• Blood Tubing Sets
• Prefilled Anticoagulant Kits
• Priming / Rinse Sets
• Bubble Traps & Pressure Sensors
• Plasma Exchange / Apheresis (TPE / TPA)
• Plasma Filters (Plasma Separators)
• Plasma Separation Kits
• Tubing and Collection Bags
• Return Filters
• Replacement Fluid Sets
• Anticoagulation Infusion Kits
• Immunoadsorption
• Adsorber Columns (e.g., Protein A)
• Specialized Immune Complex Filters
• Closed-System Tubing and Cartridges
• Cytokine Filters
• Replacement Fluid Infusion Sets
• Others / Hybrid Modalities
• Hybrid Therapy Kits (e.g., CRRT + Hemoperfusion)
• Multi-functional Blood Filters
• Anticoagulation Delivery Kits
• Connectors, Caps, Luer Locks
• Priming Sets and Flush Kits

By Application / Clinical Indication

• Acute Kidney Injury (AKI)
• Chronic Kidney Disease / End-Stage Renal Disease
• Sepsis and Septic Shock
• Infectious Diseases
• Autoimmune & Neurological Disorders
• Guillain-Barre Syndrome
• Myasthenia Gravis
• Multiple Sclerosis
• Lupus Nephritis
• Toxin Removal / Drug Overdose
• Others
• Post-transplantation care
• Liver support therapy
• Pediatric and neonatal blood purification

By End-User

• Hospitals (General & Specialty)
• Dialysis Centers
• ICUs / Critical Care Units
• Ambulatory Surgical Centers
• Home-care Settings

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geography Breakdown

• North America is expected to maintain a dominant position throughout the 2026-2035 period, supported by a combination of strong policy frameworks, advanced healthcare infrastructure, and high levels of investment activity across the renal care ecosystem. The region's leadership is closely tied to the proactive role of the U.S. Centers for Medicare & Medicaid Services, which continues to promote and incentivize value-based kidney care models. These initiatives are designed to improve patient outcomes while simultaneously controlling long-term treatment costs, encouraging providers to adopt integrated and outcome-driven care pathways for chronic kidney disease and end-stage renal disease management.
• In addition to supportive reimbursement structures, the market strength in North America is reinforced by the dense presence of Tier-1 original equipment manufacturers that continuously introduce technologically advanced dialysis systems and related renal care solutions. This competitive landscape accelerates innovation, improves device accessibility, and strengthens supply chains across both in-center and home-based treatment settings. The region also benefits from a mature regulatory environment that facilitates relatively faster adoption of next-generation therapies compared to many other global markets.

Leading Market Participants

• Aethlon Medical, Inc.
• Asahi Kasei Medical Co., Ltd.
• B. Braun Melsungen AG
• Baxter International Inc.
• Cerus Corporation
• CytoSorbents Corporation
• ExThera Medical Corporation
• Fresenius Medical Care AG & Co. KGaA
• Guangzhou Baiyunshan Biomedical
• Haemonetics Corporation
• Jafron Biomedical Co., Ltd.
• JMS Co., Ltd.
• Kaneka Corporation
• Kawasumi Laboratories Inc.
• Medtronic plc
• Nikkiso Co., Ltd.
• Nipro Corporation
• Terumo Corporation
• Toray Medical Co., Ltd.
• Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Blood Purification Equipment Market

Chapter 2. Research Methodology & Research Framework

• 2.1. Research Objective
• 2.2. Product Overview
• 2.3. Market Segmentation
• 2.4. Qualitative Research
  • 2.4.1. Primary & Secondary Sources
• 2.5. Quantitative Research
  • 2.5.1. Primary & Secondary Sources
• 2.6. Breakdown of Primary Research Respondents, By Region
• 2.7. Assumption for Study
• 2.8. Market Size Estimation
• 2.9. Data Triangulation

Chapter 3. Global Blood Purification Equipment Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. Raw Material & Component Sourcing
  • 3.1.2. Product Design & R&D
  • 3.1.3. Manufacturing & Assembly
  • 3.1.4. Quality Assurance & Regulatory Compliance
  • 3.1.5. Distribution & Logistics
  • 3.1.6. Sales, After-Sales Service & Clinical Support
• 3.2. Industry Outlook
  • 3.2.1. Sepsis Cases in the World
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of Substitutes
  • 3.4.4. Threat of New Entrants
  • 3.4.5. Degree of Competition
• 3.5. Market Growth and Outlook
  • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.5.2. Price Trend Analysis, By Modality

Chapter 4. Global Blood Purification Equipment Market Analysis

• 4.1. Competition Dashboard
  • 4.1.1. Market Concentration Rate
  • 4.1.2. Company Market Share Analysis (Value %), 2025
  • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Blood Purification Equipment Market Analysis

• 5.1. Market Dynamics and Trends
  • 5.1.1. Growth Drivers
  • 5.1.2. Restraints
  • 5.1.3. Opportunity
  • 5.1.4. Key Trends
• 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 5.2.1. By Modality
    • 5.2.1.1. Key Insights
      • 5.2.1.1.1. Hemodialysis (HD)
        • 5.2.1.1.1.1. Dialyzers (Hemodialysis filters)
        • 5.2.1.1.1.2. Bloodlines and Tubing Sets
        • 5.2.1.1.1.3. AV Fistula Needles
        • 5.2.1.1.1.4. Dialysate Connectors and Cartridges
        • 5.2.1.1.1.5. Drip Chambers
        • 5.2.1.1.1.6. Heparin Lines / Syringe Sets
        • 5.2.1.1.1.7. Inline Filters / Air Traps
      • 5.2.1.1.2. Continuous Renal Replacement Therapy (CRRT)
        • 5.2.1.1.2.1. Hemofilters (CRRT filters)
        • 5.2.1.1.2.2. CRRT Tubing Sets / Circuits
        • 5.2.1.1.2.3. Replacement Fluid / Dialysate Bags
        • 5.2.1.1.2.4. Access Catheters (Double/Triple Lumen)
        • 5.2.1.1.2.5. Flush Kits / Priming Sets
        • 5.2.1.1.2.6. Pressure Monitoring Line Sets
        • 5.2.1.1.2.7. Anticoagulation Cartridges / Lines
      • 5.2.1.1.3. Hemoperfusion
        • 5.2.1.1.3.1. Hemoperfusion Cartridges (Resin/Charcoal)
        • 5.2.1.1.3.2. Adsorber Column Connectors
        • 5.2.1.1.3.3. Blood Tubing Sets
        • 5.2.1.1.3.4. Prefilled Anticoagulant Kits
        • 5.2.1.1.3.5. Priming / Rinse Sets
        • 5.2.1.1.3.6. Bubble Traps & Pressure Sensors
      • 5.2.1.1.4. Plasma Exchange / Apheresis (TPE / TPA)
        • 5.2.1.1.4.1. Plasma Filters (Plasma Separators)
        • 5.2.1.1.4.2. Plasma Separation Kits
        • 5.2.1.1.4.3. Tubing and Collection Bags
        • 5.2.1.1.4.4. Return Filters
        • 5.2.1.1.4.5. Replacement Fluid Sets
        • 5.2.1.1.4.6. Anticoagulation Infusion Kits
      • 5.2.1.1.5. Immunoadsorption
        • 5.2.1.1.5.1. Adsorber Columns (e.g., Protein A)
        • 5.2.1.1.5.2. Specialized Immune Complex Filters
        • 5.2.1.1.5.3. Closed-System Tubing and Cartridges
        • 5.2.1.1.5.4. Cytokine Filters
        • 5.2.1.1.5.5. Replacement Fluid Infusion Sets
      • 5.2.1.1.6. Others / Hybrid Modalities
        • 5.2.1.1.6.1. Hybrid Therapy Kits (e.g., CRRT + Hemoperfusion)
        • 5.2.1.1.6.2. Multi-functional Blood Filters
        • 5.2.1.1.6.3. Anticoagulation Delivery Kits
        • 5.2.1.1.6.4. Connectors, Caps, Luer Locks
        • 5.2.1.1.6.5. Priming Sets and Flush Kits
  • 5.2.2. By Application / Clinical Indication
    • 5.2.2.1. Key Insights
      • 5.2.2.1.1. Acute Kidney Injury (AKI)
      • 5.2.2.1.2. Chronic Kidney Disease / End-Stage Renal Disease
      • 5.2.2.1.3. Sepsis and Septic Shock
      • 5.2.2.1.4. Infectious Diseases
      • 5.2.2.1.5. Autoimmune & Neurological Disorders
        • 5.2.2.1.5.1. Guillain-Barre Syndrome
        • 5.2.2.1.5.2. Myasthenia Gravis
        • 5.2.2.1.5.3. Multiple Sclerosis
        • 5.2.2.1.5.4. Lupus Nephritis
        • 5.2.2.1.5.5. Toxin Removal / Drug Overdose
      • 5.2.2.1.6. Others
        • 5.2.2.1.6.1. Post-transplantation care
        • 5.2.2.1.6.2. Liver support therapy
        • 5.2.2.1.6.3. Pediatric and neonatal blood purification
  • 5.2.3. By End User
    • 5.2.3.1. Key Insights
      • 5.2.3.1.1. Hospitals (General & Specialty)
      • 5.2.3.1.2. Dialysis Centers
      • 5.2.3.1.3. ICUs / Critical Care Units
      • 5.2.3.1.4. Ambulatory Surgical Centers
      • 5.2.3.1.5. Home-care Settings
  • 5.2.4. By Region
    • 5.2.4.1. Key Insights
      • 5.2.4.1.1. North America
        • 5.2.4.1.1.1. The U.S.
        • 5.2.4.1.1.2. Canada
        • 5.2.4.1.1.3. Mexico
      • 5.2.4.1.2. Europe
        • 5.2.4.1.2.1. Western Europe
          • 5.2.4.1.2.1.1. The UK
          • 5.2.4.1.2.1.2. Germany
          • 5.2.4.1.2.1.3. France
          • 5.2.4.1.2.1.4. Italy
          • 5.2.4.1.2.1.5. Spain
          • 5.2.4.1.2.1.6. Rest of Western Europe
        • 5.2.4.1.2.2. Eastern Europe
          • 5.2.4.1.2.2.1. Poland
          • 5.2.4.1.2.2.2. Russia
          • 5.2.4.1.2.2.3. Rest of Eastern Europe
      • 5.2.4.1.3. Asia Pacific
        • 5.2.4.1.3.1. China
        • 5.2.4.1.3.2. India
        • 5.2.4.1.3.3. Japan
        • 5.2.4.1.3.4. South Korea
        • 5.2.4.1.3.5. Australia & New Zealand
        • 5.2.4.1.3.6. ASEAN
          • 5.2.4.1.3.6.1.1. Indonesia
          • 5.2.4.1.3.6.1.2. Malaysia
          • 5.2.4.1.3.6.1.3. Thailand
          • 5.2.4.1.3.6.1.4. Singapore
          • 5.2.4.1.3.6.1.5. Rest of ASEAN
        • 5.2.4.1.3.7. Rest of Asia Pacific
      • 5.2.4.1.4. Middle East & Africa
        • 5.2.4.1.4.1. UAE
        • 5.2.4.1.4.2. Saudi Arabia
        • 5.2.4.1.4.3. South Africa
        • 5.2.4.1.4.4. Rest of MEA
      • 5.2.4.1.5. South America
        • 5.2.4.1.5.1. Argentina
        • 5.2.4.1.5.2. Brazil
        • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

• 6.1. Market Dynamics and Trends
  • 6.1.1. Growth Drivers
  • 6.1.2. Restraints
  • 6.1.3. Opportunity
  • 6.1.4. Key Trends
• 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 6.2.1. Key Insights
    • 6.2.1.1. By Modality
    • 6.2.1.2. By Application / Clinical Indication
    • 6.2.1.3. By End User
    • 6.2.1.4. By Country

Chapter 7. Europe Market Analysis

• 7.1. Market Dynamics and Trends
  • 7.1.1. Growth Drivers
  • 7.1.2. Restraints
  • 7.1.3. Opportunity
  • 7.1.4. Key Trends
• 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 7.2.1. Key Insights
    • 7.2.1.1. By Modality
    • 7.2.1.2. By Application / Clinical Indication
    • 7.2.1.3. By End User
    • 7.2.1.4. By Country

Chapter 8. Asia Pacific Market Analysis

• 8.1. Market Dynamics and Trends
  • 8.1.1. Growth Drivers
  • 8.1.2. Restraints
  • 8.1.3. Opportunity
  • 8.1.4. Key Trends
• 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 8.2.1. Key Insights
    • 8.2.1.1. By Modality
    • 8.2.1.2. By Application / Clinical Indication
    • 8.2.1.3. By End User
    • 8.2.1.4. By Country

Chapter 9. Middle East & Africa Market Analysis

• 9.1. Market Dynamics and Trends
  • 9.1.1. Growth Drivers
  • 9.1.2. Restraints
  • 9.1.3. Opportunity
  • 9.1.4. Key Trends
• 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 9.2.1. Key Insights
    • 9.2.1.1. By Modality
    • 9.2.1.2. By Application / Clinical Indication
    • 9.2.1.3. By End User
    • 9.2.1.4. By Country

Chapter 10. South America Market Analysis

• 10.1. Market Dynamics and Trends
  • 10.1.1. Growth Drivers
  • 10.1.2. Restraints
  • 10.1.3. Opportunity
  • 10.1.4. Key Trends
• 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 10.2.1. Key Insights
    • 10.2.1.1. By Modality
    • 10.2.1.2. By Application / Clinical Indication
    • 10.2.1.3. By End User
    • 10.2.1.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 11.1. Aethlon Medical, Inc.
• 11.2. Asahi Kasei Medical Co., Ltd.
• 11.3. B. Braun Melsungen AG
• 11.4. Baxter International Inc.
• 11.5. Cerus Corporation
• 11.6. CytoSorbents Corporation
• 11.7. ExThera Medical Corporation
• 11.8. Fresenius Medical Care AG & Co. KGaA
• 11.9. Guangzhou Baiyunshan Biomedical
• 11.10. Haemonetics Corporation
• 11.11. Jafron Biomedical Co., Ltd.
• 11.12. JMS Co., Ltd.
• 11.13. Kaneka Corporation
• 11.14. Kawasumi Laboratories Inc.
• 11.15. Medtronic plc
• 11.16. Nikkiso Co., Ltd.
• 11.17. Nipro Corporation
• 11.18. Terumo Corporation
• 11.19. Toray Medical Co., Ltd.
• 11.20. Other Prominent Players

Chapter 12. Annexure

• 12.1. List of Secondary Sources
• 12.2. Key Country Markets- Macro Economic Outlook/Indicators